New hope from old drugs in fight against Parkinson's (Update)

August 31, 2017 by Amy Norton, Healthday Reporter
Representative images illustrating TH+ neurons in the substantia nigra pars compacta (SNpc). MPTPtreated animals show loss of TH+ neurons relative to control animals treated with saline or saline plus clenbuterol. Scale bar, 100 mm. Credit: S. Mittal et al., Science (2017)

Scientists have found early hints that compounds in certain asthma drugs might be able to combat Parkinson's disease.

The researchers cautioned that their findings are only a first step. Much more work is needed before they can lead to any new treatment for Parkinson's.

The compounds are known as beta-2 adrenergic agonists, and they are mainly found in drugs that treat asthma and certain other lung conditions by dilating the airways. They include medications such as albuterol (ProAir, Ventolin) and metaproterenol.

The new study, published Sept. 1 in Science, found that the compounds appear to dampen activity in a gene implicated in Parkinson's disease.

"We think this is an exciting potential pathway to developing new treatments for Parkinson's," said senior researcher Dr. Clemens Scherzer. He's a neurologist at Brigham and Women's Hospital and Harvard Medical School in Boston.

But he cautioned against jumping to conclusions. Doctors should not start prescribing asthma medications to their Parkinson's patients.

A researcher who wrote an editorial accompanying the study agreed.

"The big caution here is that these are FDA-approved medications, and doctors could prescribe them off-label," said Dr. Evan Snyder, a professor at Sanford Burnham Prebys Medical Discovery Institute in San Diego.

He was referring to the fact that doctors are allowed to prescribe drugs for reasons other than their officially approved uses.

"My worry is that people might take these drugs in an unregulated fashion," said Snyder.

That said, he called the new findings promising. "I think this is enough to justify moving toward properly done clinical trials," Snyder said.

Parkinson's is a movement disorder that affects nearly 1 million people in the United States alone, according to the Parkinson's Disease Foundation.

The root cause is unclear, but as the disease progresses, the brain loses cells that produce dopamine—a chemical that regulates movement. That results in symptoms such as tremors, stiff limbs, and balance and coordination problems that gradually worsen over time.

Many people with Parkinson's have a buildup of protein clumps, called Lewy bodies, in the brain. They mainly consist of a protein called alpha-synuclein.

Scientists aren't sure whether that protein buildup is actually a cause of Parkinson's or just "collateral damage" from the disease process, Snyder said.

But, he added, mutations in the alpha-synuclein gene have been implicated as one cause of rare, inherited cases of Parkinson's.

According to Scherzer, there's also evidence that "risk variants" of the alpha-synuclein gene can contribute to more common forms of Parkinson's.

Researchers are already trying to develop drugs that target alpha-synuclein—by clearing it from the brain, for example. Scherzer said his team took a different approach.

"We thought the best way to tackle this might be to 'turn down' the production of alpha-synuclein," he explained.

So the researchers screened more than 1,100 compounds—from prescription drugs to vitamins and herbs—to find any that curbed activity in the alpha-synuclein gene.

Beta-2 agonists turned out to be a winner.

Next, the researchers turned to a Norwegian database that tracks all drug prescriptions in that country. Out of more than 4 million people, Scherzer's team identified 600,000-plus who'd used the asthma drug salbutamol (called albuterol in the United States).

Overall, those people were one-third less likely to develop Parkinson's over 11 years, versus non-users. In contrast, Parkinson's risk was doubled among people who'd ever used the blood pressure drug propranolol (Inderal).

Propranolol is a beta-blocker—a class of medications normally used to treat blood pressure and heart disease. The researchers found that beta-blockers may actually increase activity in the alpha-synuclein gene, Scherzer said.

However, he stressed, the findings do not prove that asthma drugs prevent Parkinson's—or that beta-blockers contribute to it.

"You need a clinical trial to prove cause-and-effect," Scherzer said.

He did, however, caution on rushing to a clinical trial. To Scherzer, it would be wise to try to refine the beta-2 agonist compounds, to make them more effective at dialing down alpha-synuclein.

He also said any future studies could focus on Parkinson's patients who carry variants of the alpha-synuclein gene that have been tied to the disease.

Snyder agreed that any effects of beta-2 agonists might vary based on individuals' genetics.

The findings raise another, more immediate question: What about Parkinson's patients who are on beta-blockers—the drugs linked to a higher risk of the disease?

Both Snyder and Scherzer stressed that they should not abandon any medications they need for high blood pressure or heart disease.

But, Scherzer said, patients who are concerned could ask their doctor whether there are any alternative medications.

Explore further: Drug discovery: Alzheimer's and Parkinson's spurred by same enzyme

More information: S. Mittal el al., "β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson's disease," Science (2017). science.sciencemag.org/cgi/doi … 1126/science.aaf3934

Related Stories

Drug discovery: Alzheimer's and Parkinson's spurred by same enzyme

July 3, 2017
Alzheimer's disease and Parkinson's disease are not the same. They affect different regions of the brain and have distinct genetic and environmental risk factors.

CRISPR tech leads to new screening tool for Parkinson's disease

June 5, 2017
A team of researchers at the University of Central Florida is using breakthrough gene-editing technology to develop a new screening tool for Parkinson's disease, a debilitating degenerative disorder of the nervous system. ...

A new insight into Parkinson's disease protein

July 28, 2017
Abnormal clumps of certain proteins in the brain are a prominent feature of Parkinson's and other neurodegenerative diseases, but the role those same proteins might play in the normal brain has been unknown.

A better model for Parkinson's disease

February 1, 2016
Scientists at EPFL solve a longstanding problem with modeling Parkinson's disease in animals. Using newfound insights, they improve both cell and animal models for the disease, which can propel research and drug development.

Pre-clinical study suggests Parkinson's could start in gut endocrine cells

June 15, 2017
Recent research on Parkinson's disease has focused on the gut-brain connection, examining patients' gut bacteria, and even how severing the vagus nerve connecting the stomach and brain might protect some people from the debilitating ...

Research provides new understanding of Parkinson's and Alzheimer's disease and opens path to treatment

October 26, 2016
A team of scientists at Baylor College of Medicine and Texas Children's Hospital has discovered that in three separate laboratory models, the protein TRIM28 can promote the accumulation of two key proteins that drive the ...

Recommended for you

New method maps the dopamine system in Parkinson's patients

February 14, 2018
With the aid of a PET camera, researchers from Karolinska Institutet in Sweden have developed a new method for investigating the dopamine system in the brains of patients suffering from Parkinson's disease. The method measures ...

Mechanism behind common Parkinson's mutation discovered

February 5, 2018
Northwestern Medicine investigators have discovered how a gene mutation results in buildup of a toxic compound known to cause Parkinson's disease symptoms, defining for the first time the mechanism underlying that aspect ...

Tactic for controlling motor symptoms of advanced Parkinson's disease

January 25, 2018
Standard drug treatment for Parkinson's disease can over time induce motor complications that reduce the effectiveness of restoring mobility. These complications include abnormal involuntary movements known as dyskinesias. ...

A new therapeutic avenue for Parkinson's disease

January 23, 2018
Systemic clearing of senescent astrocytes prevents Parkinson's neuropathology and associated symptoms in a mouse model of sporadic disease, the type implicated in 95% of human cases. Publishing in Cell Reports, researchers ...

Investigators eye new target for treating movement disorders

January 19, 2018
Blocking a nerve-cell receptor in part of the brain that coordinates movement could improve the treatment of Parkinson's disease, dyskinesia and other movement disorders, researchers at Vanderbilt University have reported.

Parkinson's disease 'jerking' side effect detected by algorithm

January 8, 2018
A mathematical algorithm that can reliably detect dyskinesia, the side effect from Parkinson's treatment that causes involuntary jerking movements and muscle spasms, could hold the key to improving treatment and for patients ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.